Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -1977.59% is 20% below its 5-year average of -1645.05%, near the high end of its 5-year range (-9568.25%–-571.67%).
15.19% above its 12-month average of -2331.89%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -2116.03%.
NET PROFIT MARGIN
-1977.59%
NET PROFIT MARGIN AVG TTM
-2331.89%
NET PROFIT MARGIN AVG 3Y
-1807.69%
NET PROFIT MARGIN AVG 5Y
-1645.05%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+15.19%
CURRENT VS 3Y AVG
-9.40%
CURRENT VS 5Y AVG
-20.21%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-760511.54%
vs the sector median at left
Longeveron Inc.
Market Cap
$7.20M
Net Profit Margin
-1977.59%
TTM Avg
-2331.89%
3Y Avg
-1807.69%
5Y Avg
-1645.05%
Market Cap
$7.08M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.32M
Net Profit Margin
-0.61%
TTM Avg
-82.77%
3Y Avg
-131.16%
5Y Avg
-372.00%
Market Cap
$7.04M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-19.45%
5Y Avg
-19.45%
Market Cap
$6.91M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-287.91%
5Y Avg
-676.70%
Market Cap
$7.01M
Net Profit Margin
0.00%
TTM Avg
-970.10%
3Y Avg
-487.29%
5Y Avg
1862.33%
Market Cap
$7.47M
Net Profit Margin
-4791.48%
TTM Avg
-2970.23%
3Y Avg
-7387.99%
5Y Avg
-5910.39%
Market Cap
$7.53M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.94M
Net Profit Margin
-6523.04%
TTM Avg
-4247.49%
3Y Avg
-2263.82%
5Y Avg
-1493.48%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Longeveron Inc. (LGVN) | $7.20M | -1977.59% | -2331.89% | -1807.69% | -1645.05% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | 0.00% | 0.00% | 0.00% | 0.00% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.32M | -0.61% | -82.77% | -131.16% | -372.00% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.04M | 0.00% | 0.00% | -19.45% | -19.45% |
| KALA BIO, Inc. (KALA)vs › | $6.91M | 0.00% | 0.00% | -287.91% | -676.70% |
| Exicure, Inc. (XCUR)vs › | $7.01M | 0.00% | -970.10% | -487.29% | 1862.33% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.47M | -4791.48% | -2970.23% | -7387.99% | -5910.39% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.53M | 0.00% | 0.00% | 0.00% | 0.00% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.94M | -6523.04% | -4247.49% | -2263.82% | -1493.48% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.78M | -611.47% | -627.26% | -917.71% | -6297.45% |
Operating Margin
-1942.2%
Net Profit Margin
-1977.6%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -2116.03% |
| 2026-03-31 | -1189.95% |
| 2025-12-31 | -1491.51% |
| 2025-09-30 | -5270.80% |
| 2025-06-30 | -1591.14% |
| 2025-03-31 | -1315.22% |
| 2024-12-31 | -676.78% |
| 2024-09-30 | -571.67% |
| 2024-06-30 | -729.27% |
| 2024-03-31 | -740.51% |
| 2023-12-31 | -9568.25% |
| 2023-09-30 | -3404.00% |
| 2023-06-30 | -2595.39% |
| 2023-03-31 | -1952.52% |
| 2022-12-31 | -3683.47% |
| 2022-09-30 | -1978.87% |
| 2022-06-30 | -1206.87% |
| 2022-03-31 | -948.65% |
| 2021-12-31 | -1946.89% |
| 2021-09-30 | -2092.67% |
| 2021-06-30 | -1024.54% |
| 2021-03-31 | -827.39% |
| 2020-12-31 | -114.93% |
| 2020-09-30 | -50.29% |
| 2020-06-30 | -138.81% |
| 2020-03-31 | -12.47% |
| 2019-12-31 | -25.70% |
